文献速递淋巴瘤

确定弥漫性大B细胞淋巴瘤患者晚期复发风险的临床和治疗相关特征

Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma.
PubMed 文献 · Br J Haematol · 2017-06-27

基于丹麦淋巴瘤组登记处7247例弥漫性大B细胞淋巴瘤(DLBCL)患者数据,分析晚期复发(LR)的频率、影响因素及利妥昔单抗引入对LR的影响。LR患者较早期复发(ER)患者国际预后指数更低、体能状态更好,且5年总生存显著更优。利妥昔单抗降低ER和LR发生率(均P<0.0001),放疗仅降低ER率。

要点

  • 晚期复发患者较早期复发患者国际预后指数更低、体能状态更好。
  • 利妥昔单抗降低早期和晚期复发发生率(均P<0.0001),放疗仅降低早期复发率。
  • 晚期复发患者5年总生存显著优于早期复发患者。

核心结论

  • 晚期复发较早期复发更常与低危特征相关。
  • 现代免疫化疗方案降低DLBCL早期和晚期复发风险。

研究设计与样本

  • 基于丹麦淋巴瘤组登记处的7247例DLBCL患者的人群队列研究。

主要发现

  • 晚期复发患者国际预后指数低于早期复发患者,体能状态评分优于早期复发患者。
  • 放疗仅降低早期复发率,利妥昔单抗降低早期和晚期复发发生率(P<0.0001和P<0.0001)。
  • 接受含利妥昔单抗一线治疗的晚期复发患者中女性比例过高。
  • 晚期复发患者5年总生存显著优于早期复发患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is still unclear whether there are clinically exploitable differences in the biology and behaviour of early versus late relapses in diffuse large B-cell lymphoma (DLBCL). The present study aimed to analyse a large population-based DLBCL cohort in order to identify (i) the frequency of late relapses (LR), (ii) parameters influencing the risk of LR, and (iii) the impact of introducing rituximab on the occurrence of LR. The data of 7247 DLBCL patients was obtained from the Danish Lymphoma Group Registry. Patients with LR had a lower International Prognostic Index and better performance score than early relapse (ER) patients. The use of radiotherapy lowered only the rate of ER while the use of rituximab yielded a lower occurrence of both ER and LR (P < 0·0001 and P < 0·0001, respectively), possibly suggesting a longer-lasting biological effect. Additionally, we found a female overrepresentation among LR patients that had received a rituximab-containing first line treatment. It was found that patients with LR had a significantly better 5-year overall survival compared to ER patients. In conclusion, LR was more frequently associated with low-risk features than ER. Furthermore, we found that the use of modern immunochemotherapy regimens in DLBCL lowers the risk of both ER and LR.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Modvig L, Vase M, d'Amore F, et al. Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma. Br J Haematol. 2017. PMID: 28653321. doi:10.1111/bjh.14822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。